NSAIDs/Nitazoxanide/Azithromycin Immunomodulatory COVID Protocol Might Inhibit SARS CoV-2 Replication Through Disruption of NF-κB Signaling

Updated, peer reviewed and published https://link.springer.com/article/10.1007/s10787-021-00896-7#Sec7 In March 2020, I’ve sent a correspondence to NEJM (20-06753) calling the claims that led the world to avoid non-steroidal anti-inflammatory drugs in COVID-19 management as a scam and it was rejected by this journal as well as more than a dozen of other journals until published almost six months later at the reputable InflammoPharmacology. In April 2020, a concept paper was rapidly published as a letter to the editor favoring nitazoxanide over ivermectin for management of COVID-19 together with azithromycin. Since then, a protocol has evolved to safely manage dozens of pediatric, geriatric, adult and pregnant COVID-19 patients and it was rejected by dozens of journals since May 2020 (20-19376) and eventually it was published in August 2021 only after publishing several papers to justify its academic basis in highly reputable journals. I repeat my long-ignored claim NSAIDs/Nitazoxanide/Azithromycin immunomodulatory protocol (Kelleni’s Protocol) a game-changer that might end this pandemic safely and immediately and, in this manuscript, I’m adding more recent evidence that justify my claim.